Acuta Capital Partners, LLC Aclaris Therapeutics, Inc. Transaction History

Acuta Capital Partners, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$7.89 - $10.64 $1,167 - $1,574	-148 Reduced 0.12%	121,692 $1.26 Million
Q1 2023 May 15, 2023	SELL	$7.07 - $17.95 $941,441 - $2.39 Million	-133,160 Reduced 52.22%	121,840 $985,000
Q4 2022 Feb 14, 2023	BUY	$14.33 - $18.37 $1.35 Million - $1.73 Million	94,165 Added 58.55%	255,000 $4.02 Million
Q3 2022 Nov 14, 2022	SELL	$13.07 - $18.22 $418,240 - $583,040	-32,000 Reduced 16.59%	160,835 $2.53 Million
Q2 2022 Aug 15, 2022	SELL	$10.16 - $17.08 $251,612 - $422,986	-24,765 Reduced 11.38%	192,835 $2.69 Million
Q1 2022 May 16, 2022	BUY	$9.74 - $17.92 $1.16 Million - $2.14 Million	119,600 Added 122.04%	217,600 $3.75 Million
Q4 2021 Feb 14, 2022	SELL	$12.27 - $18.49 $525,634 - $792,093	-42,839 Reduced 30.42%	98,000 $1.43 Million
Q3 2021 Nov 15, 2021	SELL	$13.38 - $18.8 $457,074 - $642,226	-34,161 Reduced 19.52%	140,839 $2.54 Million
Q2 2021 Aug 16, 2021	SELL	$17.08 - $29.6 $2.44 Million - $4.22 Million	-142,730 Reduced 44.92%	175,000 $3.07 Million
Q1 2021 May 17, 2021	BUY	$5.86 - $27.73 $1.86 Million - $8.81 Million	317,730 New	317,730 $8.01 Million
Q1 2018 May 15, 2018	SELL	$17.08 - $25.64 $1.58 Million - $2.37 Million	-92,500 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$21.47 - $27.8 $1.99 Million - $2.57 Million	92,500	92,500 $2.28 Million

50.7M

30.6K

Ticker ACRS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 66,671,800
Market Cap $255M
Description
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.